{"entity":{"id":"oncoseek","kind":"drug","name":"OncoSeek","aka":[],"tldr":"SeekIn's low-cost protein blood test for 14 cancers, designed for countries that cannot afford DNA sequencing; it finds about six in ten cancers but flags about one in twelve people without cancer.","summary":"OncoSeek combines seven protein tumour markers with age and sex. In the pooled validation (Shen et al., npj Precision Oncology 2025; 15,122 participants, 3,029 with cancer, seven centres in three countries) it had an area under the curve of 0.829, 58.4% sensitivity, 92.0% specificity and 70.6% tissue-of-origin accuracy in true positives, across 14 cancer types with sensitivities of 38.9% to 83.3%. The first study (Luan et al., eClinicalMedicine 2023; 7,565 participants plus a Johns Hopkins validation cohort) reported 51.7% sensitivity and 92.9% specificity.\n\nAt 92% specificity about 8 in 100 people without cancer test positive, far more than with DNA-based tests run at 98 to 99.5%, so in a screening population most positives would not be cancer. SeekIn's website claims 14 high-mortality cancers with the same 58.4% and 92.0% figures; CE marking was reported in September 2022 for 12 cancers. No NMPA or FDA status, price or registered trial was found.","status":"emerging","asOf":"2026-10-29","links":[{"label":"SeekIn: OncoSeek","url":"https://www.seekincancer.com/oncoseek"},{"label":"Shen et al., npj Precision Oncology 2025","url":"https://doi.org/10.1038/s41698-025-01105-2"},{"label":"Luan et al., eClinicalMedicine 2023","url":"https://doi.org/10.1016/j.eclinm.2023.102041"}],"tags":["test","mced","evidence:insufficient"],"related":["seekincare"],"cancers":[],"sections":[],"technologies":["mced","liquid-biopsy","proteomics"],"targets":[],"drugs":[],"companies":["seekin"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-oncoseek-eclinicalmedicine-2023","paper-oncoseek-npj-precis-oncol-2025"],"journals":[],"dependsOn":[],"notes":["Evidence grade insufficient for the claim that taking this test reduces late-stage diagnosis or cancer deaths: no randomised trial of it has reported either outcome, and its published performance comes from case-control or single-arm studies. The only randomised result for any multi-cancer test, NHS-Galleri, did not show fewer stage III or IV cancers.","What a result means: a positive result is a reason for further tests, not a diagnosis; a negative result does not rule cancer out and does not replace the screening tests that have been shown to work (bowel, breast, cervical and, where eligible, lung screening)."],"brand":"OncoSeek","modality":"Multi-cancer blood test (seven protein tumour markers with artificial intelligence)","mechanism":"Seven protein tumour markers measured on a standard clinical immunoassay analyser, combined with age and sex by an artificial intelligence model that gives a probability of cancer and a likely tissue of origin.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/oncoseek/","neighbours":{"drug":[{"id":"seekincare","kind":"drug","name":"SeekInCare","route":"/drugs/seekincare/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"},{"id":"proteomics","kind":"technology","name":"Proteomics & phosphoproteomics","route":"/technologies/proteomics/"}],"company":[{"id":"seekin","kind":"company","name":"SeekIn","route":"/companies/seekin/"}],"paper":[{"id":"paper-oncoseek-npj-precis-oncol-2025","kind":"paper","name":"A large-scale, multi-centre validation study of an AI-empowered blood-based test for multi-cancer early detection","route":"/key-papers/paper-oncoseek-npj-precis-oncol-2025/"},{"id":"paper-oncoseek-eclinicalmedicine-2023","kind":"paper","name":"A panel of seven protein tumour markers for effective and affordable multi-cancer early detection by artificial intelligence: a large-scale and multicentre case-control study","route":"/key-papers/paper-oncoseek-eclinicalmedicine-2023/"}]}}